Related Experiment Video

Updated: Dec 31, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.8K

Management of dyslipidemia in pediatric renal transplant recipients

Margret E Bock1, Leslie Wall2, Carly Dobrec2

  • 1Section of Pediatric Nephrology, Children's Hospital Colorado, University of Colorado, Aurora, CO, USA.

Pediatric Nephrology (Berlin, Germany)
|January 4, 2020
PubMed

Insights

Post-transplant dyslipidemia is a common issue, particularly in children, increasing cardiovascular risk. This review covers guidelines for managing pediatric dyslipidemia after kidney transplant and highlights areas for improved care.

Area of Science:

  • Nephrology
  • Pediatric Nephrology
  • Cardiology

Background:

  • Dyslipidemia is a frequent complication following kidney transplantation.
  • It represents a significant, modifiable risk factor for cardiovascular disease (CVD) in transplant recipients.
  • CVD is a leading cause of death and illness in this patient population.

Purpose of the Study:

  • To review current recommendations and treatment strategies for dyslipidemia in pediatric kidney transplant recipients.
  • To highlight the need for increased awareness and comprehensive management approaches.
  • To identify areas for quality improvement in managing post-transplant dyslipidemia in children.

Main Methods:

  • Literature review focusing on post-transplant dyslipidemia in adult and pediatric kidney transplant patients.
  • Synthesis of existing guidelines and treatment protocols.
  • Identification of knowledge gaps and areas for future research and quality improvement.

Main Results:

  • Dyslipidemia is common and underappreciated in pediatric kidney transplant recipients.
  • Established guidelines for adult dyslipidemia management are applicable to children.
  • Current awareness and application of guidelines are insufficient for optimal patient care.

Conclusions:

  • Effective management of post-transplant dyslipidemia in children requires awareness of existing guidelines.
  • Additional strategies and quality improvement initiatives are necessary for comprehensive care.
  • Addressing dyslipidemia is crucial for reducing cardiovascular morbidity and mortality in pediatric transplant patients.

Keywords:
CholesterolDyslipidemiaKidneyPediatricTransplantTriglycerides

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
168
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
152
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
270
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
282
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
281